Stephan Targan

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. ncbi request reprint High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study
    William S Mow
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, California 90048, USA
    Dig Dis Sci 49:1280-6. 2004
  2. pmc IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein
    Kathrin S Michelsen
    Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    PLoS ONE 4:e4719. 2009
  3. pmc High-frequency haplotypes in the X chromosome locus TLR8 are associated with both CD and UC in females
    Masayuki Saruta
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center and the UCLA School of Medicine, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 15:321-7. 2009
  4. pmc MAGI2 genetic variation and inflammatory bowel disease
    Dermot P B McGovern
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 15:75-83. 2009
  5. pmc Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement development
    Masato Mitsuhashi
    Hitachi Chemical Research Center Inc, Irvine, CA, USA
    Pharm Res 25:1116-24. 2008
  6. pmc TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets
    Stephanie C Heidemann
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, 8700 Beverly Blvd, D4063, Los Angeles, CA, 90048, USA
    J Clin Immunol 30:531-8. 2010
  7. ncbi request reprint Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease
    Stephan R Targan
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    Gastroenterology 128:2020-8. 2005
  8. ncbi request reprint Defects in mucosal immunity leading to ulcerative colitis
    Stephan R Targan
    Division of Gastroenterology, Inflammatory Bowel Disease Center, Immunobiology Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Immunol Rev 206:296-305. 2005
  9. ncbi request reprint Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial
    Stephan R Targan
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 132:1672-83. 2007
  10. ncbi request reprint Inflammatory bowel disease diagnosis, evaluation and classification: state-of-the art approach
    Stephan R Targan
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    Curr Opin Gastroenterol 23:390-4. 2007

Research Grants

  1. Role of TL1A in Severity of Crohn's Disease Inflammation
    Stephan R Targan; Fiscal Year: 2010
  2. IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTION
    Stephan Targan; Fiscal Year: 2005
  3. IBD:TNF-alpha and Crohn's Disease Mucosal Inflammation
    Stephan Targan; Fiscal Year: 2007
  4. TNF ALPHA AND CROHNS DISEASE MUCOSAL INFLAMMATION
    Stephan Targan; Fiscal Year: 2003
  5. ROLE OF ACTIVATED T CELLS IN GUT INJURY
    Stephan Targan; Fiscal Year: 1993
  6. IBD--ROLE OF ACTIVATED T-CELLS IN GUT INJURY
    Stephan Targan; Fiscal Year: 2000

Detail Information

Publications94

  1. ncbi request reprint High-level serum antibodies to bacterial antigens are associated with antibiotic-induced clinical remission in Crohn's disease: a pilot study
    William S Mow
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center and UCLA School of Medicine, Los Angeles, California 90048, USA
    Dig Dis Sci 49:1280-6. 2004
    ..Although not statistically significant, these results support further testing to determine whether predominant serum reactivity to certain bacterial antigens may be a marker for efficacious use of antibiotics...
  2. pmc IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein
    Kathrin S Michelsen
    Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    PLoS ONE 4:e4719. 2009
    ..TL1A and its receptor DR3 are up-regulated during chronic intestinal inflammation in ulcerative colitis and Crohn's disease (CD). TL1A gene haplotypes increase CD susceptibility in Japanese, European, and US cohorts...
  3. pmc High-frequency haplotypes in the X chromosome locus TLR8 are associated with both CD and UC in females
    Masayuki Saruta
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center and the UCLA School of Medicine, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 15:321-7. 2009
    ..Interestingly, TLR8 is located on the X chromosome and inflammatory bowel disease (IBD) has been associated with abnormalities of the X chromosome. The aim was to test whether TLR8 haplotypes are associated with IBD...
  4. pmc MAGI2 genetic variation and inflammatory bowel disease
    Dermot P B McGovern
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 15:75-83. 2009
    ..Our aim was to test MAGI2 variants for association with IBD and also their role in determining intermediate hereditary phenotypes defined by antibody production to microbial antigens...
  5. pmc Ex vivo induction of mRNA in human whole blood as a new platform of drug and dietary supplement development
    Masato Mitsuhashi
    Hitachi Chemical Research Center Inc, Irvine, CA, USA
    Pharm Res 25:1116-24. 2008
    ..This model system was applied to study various fields of drug development...
  6. pmc TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets
    Stephanie C Heidemann
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, 8700 Beverly Blvd, D4063, Los Angeles, CA, 90048, USA
    J Clin Immunol 30:531-8. 2010
    ..Its ligand, death domain receptor 3 (DR3), is induced by activation on T and NK cells. Although IL-12/IL-18 induces DR3 expression on most NK cells, addition of TL1A minimally increases IFN-gamma production...
  7. ncbi request reprint Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease
    Stephan R Targan
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    Gastroenterology 128:2020-8. 2005
    ....
  8. ncbi request reprint Defects in mucosal immunity leading to ulcerative colitis
    Stephan R Targan
    Division of Gastroenterology, Inflammatory Bowel Disease Center, Immunobiology Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Immunol Rev 206:296-305. 2005
    ..The way in which this response affects the ultimate cascade of inflammatory events has yet to be determined...
  9. ncbi request reprint Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial
    Stephan R Targan
    Inflammatory Bowel Disease Center and Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 132:1672-83. 2007
    ..A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease...
  10. ncbi request reprint Inflammatory bowel disease diagnosis, evaluation and classification: state-of-the art approach
    Stephan R Targan
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California 90048, USA
    Curr Opin Gastroenterol 23:390-4. 2007
    ..This review will describe the most recent advances and discuss promising pathways for therapeutic discovery...
  11. pmc Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation
    H Takedatsu
    Division of Gastroenterology, Inflammatory Bowel Disease Center, Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gut 58:60-7. 2009
    ..Our aim was to conduct a linkage study using expression of anti-CBir1, anti-I2, anti-OmpC and ASCA as quantitative traits...
  12. pmc Both preoperative perinuclear antineutrophil cytoplasmic antibody and anti-CBir1 expression in ulcerative colitis patients influence pouchitis development after ileal pouch-anal anastomosis
    Phillip Fleshner
    Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 6:561-8. 2008
    ..The aim of this study was to assess associations of preoperative perinuclear antineutrophil cytoplasmic antibody (pANCA) and anti-CBir1 flagellin on AP or CP development...
  13. ncbi request reprint Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease
    William S Mow
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Gastroenterology 126:414-24. 2004
    ..Our aim was to determine whether expression of antibodies against Crohn's disease-related bacterial sequence and Escherichia coli outer membrane porin C is associated with distinct phenotypic manifestations...
  14. doi request reprint Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn's disease
    Quy Le
    Division of Colon and Rectal Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 19:30-6. 2013
    ..Crohn's disease (CD) is considered a contraindication to ileal pouch--anal anastomosis (IPAA). In this study, we compare outcomes of CD and ulcerative colitis (UC) patients undergoing IPAA...
  15. doi request reprint Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease?
    Evan C White
    Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 55:563-8. 2012
    ..Unplanned hospital readmission is considered to be an index of quality surgical care...
  16. doi request reprint Rigorous histopathological assessment of the colectomy specimen in patients with inflammatory bowel disease unclassified does not predict outcome after ileal pouch-anal anastomosis
    Yosef Nasseri
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Am J Gastroenterol 105:155-61. 2010
    ..We evaluated whether any histopathological feature was associated with an adverse postoperative outcome...
  17. doi request reprint Preoperative wireless capsule endoscopy does not predict outcome after ileal pouch-anal anastomosis
    Zuri Murrell
    Division of Colon and Rectal Surgery, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 53:293-300. 2010
    ..This study examined the value of preoperative wireless capsule endoscopy in predicting outcome of ileal pouch-anal anastomosis in patients with ulcerative colitis or indeterminate colitis...
  18. pmc Increased immune reactivity predicts aggressive complicating Crohn's disease in children
    Marla C Dubinsky
    Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 6:1105-11. 2008
    ..The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression...
  19. ncbi request reprint A prospective multivariate analysis of clinical factors associated with pouchitis after ileal pouch-anal anastomosis
    Phillip Fleshner
    Division of Colon and Rectal Surgery, Department of Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 5:952-8; quiz 887. 2007
    ..The aim of this study was to identify important clinical risk factors associated with AP or CP...
  20. ncbi request reprint LIGHT is constitutively expressed on T and NK cells in the human gut and can be induced by CD2-mediated signaling
    Offer Cohavy
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    J Immunol 174:646-53. 2005
    ..Quantitative analysis of LIGHT mRNA in a cohort of inflammatory bowel disease patients indicated elevated expression in biopsies from small bowel and from inflamed sites, implicating LIGHT as a mediator of mucosal inflammation...
  21. ncbi request reprint Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens
    Carol J Landers
    Cedars Sinai Medical Center Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Gastroenterology 123:689-99. 2002
    ..Our aim was to determine whether there are heterogeneous responses to these specific antigens...
  22. ncbi request reprint Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation
    John L Prehn
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    Clin Immunol 112:66-77. 2004
    ..Expression of TL1A and its receptor DR3 by lamina propria mononuclear cells (LPMC) could have significant influence on the severity of mucosal inflammation...
  23. pmc TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation
    Hidetoshi Takedatsu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Gastroenterology 135:552-67. 2008
    ..Expression of TL1A is increased in the mucosa of Crohn's disease patients and murine models of ileitis. The aim of this study was to determine the possible role of TL1A in chronic intestinal inflammation...
  24. pmc A novel NOD2/CARD15 haplotype conferring risk for Crohn disease in Ashkenazi Jews
    Kazuhito Sugimura
    Division of Medical Genetics and Inflammatory Bowel Disease Research Center, Department of Medicine, Steven Spielberg Pediatric Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Hum Genet 72:509-18. 2003
    ..In Ashkenazi Jews, unrecognized population-specific predisposing factor(s) exist on the 268S-JW1 haplotype at the IBD1 locus. This factor may contribute to the higher risk for CD in Ashkenazi Jews as compared with non-Jews...
  25. pmc Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression
    Marla C Dubinsky
    Department of Pediatrics, Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am J Gastroenterol 101:360-7. 2006
    ..We examined the association of immune responses to microbial antigens with disease behavior and prospectively determined the influence of immune reactivity on disease progression in pediatric CD patients...
  26. pmc Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease
    Chong Shen
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 14:1641-51. 2008
    ..Our aim was to determine whether CBir1 stimulates innate and antigen-specific T-cell responses in CD. We demonstrate that CBir1 enhanced IL-6 and IL-1beta production by peripheral blood (PB) monocytes...
  27. ncbi request reprint NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives
    Shane M Devlin
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 132:576-86. 2007
    ..The aim of our study was to determine if defects in innate immunity are similarly associated with increased adaptive immune responses to microbial antigens in Crohn's disease patients...
  28. pmc IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease
    Marla C Dubinsky
    Department of Pediatrics, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 13:511-5. 2007
    ..It is unknown whether IL-23R is associated with IBD in children. The aim was to examine the association of IL-23R with susceptibility to IBD in pediatric patients...
  29. pmc TLR8-mediated activation of human monocytes inhibits TL1A expression
    Masayuki Saruta
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Immunol 39:2195-202. 2009
    ..Our data demonstrate for the first time a direct interaction between TLR and TL1A signaling pathways. TLR8 activation may be an important, novel pathway for targeted treatment of Th1-mediated diseases, such as CD...
  30. ncbi request reprint CD56 marks an effector T cell subset in the human intestine
    Offer Cohavy
    Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Immunol 178:5524-32. 2007
    ..Our findings associate CD56+ T cells with the intestinal immune compartment and suggest a putative effector function in human mucosal immunity...
  31. pmc Genetic epistasis of IL23/IL17 pathway genes in Crohn's disease
    Dermot P B McGovern
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 15:883-9. 2009
    ..Genetic variants in the IL23R and IL12B have been associated with CD susceptibility. We investigated 10 genes within the IL23/IL17 pathway in a case-control study of 763 CD cases and 254 healthy controls...
  32. doi request reprint Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease
    Andrew Ippoliti
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Inflamm Bowel Dis 16:1279-85. 2010
    ....
  33. pmc Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells
    David Q Shih
    Inflammatory Bowel Disease Center and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Immunol 39:3239-50. 2009
    ..Our findings suggest a role for TL1A in pro-inflammatory APC-T cell interactions and implicate TL1A in host responses to enteric microorganisms...
  34. ncbi request reprint High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy
    William S Mow
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Gastroenterol Hepatol 2:309-13. 2004
    ..The aim of this study is to evaluate the utility of a TST as an adequate screen for TB exposure in patients with inflammatory bowel disease (IBD)...
  35. ncbi request reprint Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease
    Jacob Spivak
    Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Inflamm Bowel Dis 12:1122-30. 2006
    ..This study examines the association between clinical features and seroreactivity to these microbial and auto-antigens in predicting a clinical response to fecal diversion...
  36. pmc Molecular imaging of murine intestinal inflammation with 2-deoxy-2-[18F]fluoro-D-glucose and positron emission tomography
    Sarah Brewer
    Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
    Gastroenterology 135:744-55. 2008
    ..However, there is limited understanding of the biologic basis of mucosal FDG uptake...
  37. ncbi request reprint Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation
    Thomas Hui
    Division of Colon and Rectal Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 48:1254-62. 2005
    ..We examined whether preoperative serologic responses to these antigens were associated with Crohn's disease in indeterminate colitis patients after ileal pouch-anal anastomosis...
  38. ncbi request reprint A genome-wide association study identifies IL23R as an inflammatory bowel disease gene
    Richard H Duerr
    Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Pittsburgh, University of Pittsburgh Medical Center Presbyterian, Mezzanine Level, C Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA
    Science 314:1461-3. 2006
    ..These results and previous studies on the proinflammatory role of IL-23 prioritize this signaling pathway as a therapeutic target in inflammatory bowel disease...
  39. pmc Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis
    Gil Y Melmed
    Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Dis Colon Rectum 51:100-8. 2008
    ..Preoperative predictors for Crohn's disease post-ileal pouch-anal anastomosis have not been prospectively defined...
  40. pmc Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease
    Marla C Dubinsky
    Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 16:1357-66. 2010
    ....
  41. ncbi request reprint LIGHT expression by mucosal T cells may regulate IFN-gamma expression in the intestine
    Offer Cohavy
    Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Immunol 173:251-8. 2004
    ..Taken together, these findings suggest LIGHT-herpesvirus entry mediator mediated signaling as an important immune regulatory mechanism in mucosal inflammatory responses...
  42. ncbi request reprint Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study
    Gil Y Melmed
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, California, USA
    Clin Gastroenterol Hepatol 5:602-8; quiz 525. 2007
    ..Identification of predictors of a diagnostic change could potentially impact the management of patients with colonic inflammation. Our aim was to characterize clinical and serologic predictors of a change in diagnosis from UC to CD...
  43. pmc Genome-wide association identifies multiple ulcerative colitis susceptibility loci
    Dermot P B McGovern
    Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Nat Genet 42:332-7. 2010
    ..These data implicate approximately 30 loci in ulcerative colitis, thereby providing insight into disease pathogenesis...
  44. pmc IL23R haplotypes provide a large population attributable risk for Crohn's disease
    Kent D Taylor
    Medical Genetics Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 14:1185-91. 2008
    ..The aim of this work was to estimate the total contribution of this gene to CD risk test using a haplotype approach...
  45. ncbi request reprint Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease
    William S Mow
    Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 2:31-40. 2004
    ..The aim of this study is to assess the clinical utility of WCE in the evaluation of patients with known or suspected inflammatory bowel disease (IBD)...
  46. doi request reprint Future biologic targets for IBD: potentials and pitfalls
    Gil Y Melmed
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Department of Medicine, Cedars Sinai Medical Center, 8635 West 3rd Street, 960 W Los Angeles, CA 90048, USA
    Nat Rev Gastroenterol Hepatol 7:110-7. 2010
    ..Future biologic drug development will benefit from the early identification of subsets of patients who are most likely to respond to therapy by use of biological markers of genetic susceptibility or immunologic susceptibility...
  47. ncbi request reprint CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile
    Konstantinos A Papadakis
    Burns and Allen Research Institute and Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA
    J Immunol 171:159-65. 2003
    ..Studies on the cytokine profile and Ag specificity of this cell subset could provide important insight into small intestinal immune-mediated diseases and oral tolerance in humans...
  48. ncbi request reprint Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 123:679-88. 2002
    ..NOD2 gene mutations in CD have been described recently and may alter innate immune responses. We hypothesized that NOD2 mutations may be associated with distinct phenotypic expressions of CD...
  49. doi request reprint Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease
    Gil Y Melmed
    Department of Medicine, Cedars Sinai Medical Center, University of California, Los Angeles, California 90048, USA
    Am J Gastroenterol 105:148-54. 2010
    ..We aimed to assess the impact of immunosuppression on immune responses to pneumococcal vaccination in patients with IBD...
  50. ncbi request reprint Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
    ..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
  51. ncbi request reprint Immunogenetic phenotypes in inflammatory bowel disease
    Marla C Dubinsky
    Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    World J Gastroenterol 12:3645-50. 2006
    ....
  52. ncbi request reprint Current limitations of IBD treatment: where do we go from here?
    Stephan R Targan
    Cedars Sinai Medical Center, 8700 Beverly Blvd, Suite D4063, Los Angeles, CA 90048, USA
    Ann N Y Acad Sci 1072:1-8. 2006
    ....
  53. doi request reprint A prospective analysis of clinical variables, serologic factors, and outcome of ileal pouch-anal anastomosis in patients with backwash ileitis
    Evan White
    Division of Colon and Rectal Surgery, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 53:987-94. 2010
    ..We prospectively compared the outcomes of ileal pouch-anal anastomosis in colitis patients with backwash ileitis and colitis patients without backwash ileitis...
  54. ncbi request reprint Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa
    Konstantinos A Papadakis
    Inflammatory Bowel Disease Center and Burns and Allen Research Institute, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 10:778-88. 2004
    ..Activation-dependent receptor regulation and alteration in receptor-bearing cells, primarily in MLN draining inflamed intestinal tissue, suggest an important role for this T-cell subset in the pathogenesis of human IBD...
  55. pmc Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease
    Dermot P B McGovern
    Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Hum Mol Genet 19:3468-76. 2010
    ..001). These findings strongly implicate this locus in CD susceptibility and highlight the role of the mucus layer in the development of CD...
  56. pmc Genetic predictors of medically refractory ulcerative colitis
    Talin Haritunians
    Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 16:1830-40. 2010
    ..The aim of this study was to use a genome-wide association study (GWAS) in a well-characterized cohort of UC patients to identify genetic variation that contributes to MR-UC...
  57. ncbi request reprint Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations
    Konstantinos A Papadakis
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Inflamm Bowel Dis 13:524-30. 2007
    ..We examined the association between anti-CBir1 and clinical phenotypes and NOD2 variants in a large cohort of adult CD patients...
  58. ncbi request reprint Dominant role for TL1A/DR3 pathway in IL-12 plus IL-18-induced IFN-gamma production by peripheral blood and mucosal CCR9+ T lymphocytes
    Konstantinos A Papadakis
    Burns and Allen Research Institute, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA 90048, USA
    J Immunol 174:4985-90. 2005
    ....
  59. pmc B lymphocyte-induced maturation protein-1 contributes to intestinal mucosa homeostasis by limiting the number of IL-17-producing CD4+ T cells
    Soofia Salehi
    F Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 189:5682-93. 2012
    ..Collectively, the results described here establish a new role for Blimp-1 in regulating IL-17 production in vivo...
  60. pmc Controversies in ulcerative colitis: a survey comparing decision making of experts versus community gastroenterologists
    Brennan M R Spiegel
    Veteran s Administration Greater Los Angeles Healthcare System, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 7:168-74, 174.e1. 2009
    ..We performed a national vignette survey to measure variations in decision-making in areas of controversy...
  61. ncbi request reprint Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine
    Marla C Dubinsky
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Am J Gastroenterol 98:1058-63. 2003
    ..The aim of this study was to determine if hypersensitivity reactions to 6-MP/AZA reoccur with 6-TG therapy...
  62. ncbi request reprint Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease
    Ling Mei
    Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Gastroenterology 130:1078-85. 2006
    ..The aim of this study was to determine whether there is familial aggregation and genetic determination of anti-OmpC expression in CD families...
  63. ncbi request reprint Phenotype and effector function of CC chemokine receptor 9-expressing lymphocytes in small intestinal Crohn's disease
    Masayuki Saruta
    Inflammatory Bowel Disease Center and Immunobiology Institute, Division of Colorectal Surgery, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    J Immunol 178:3293-300. 2007
    ..Our data indicate that CCR9(+) T cells in SB CD are proinflammatory and support the rationale for the use of CCR9 antagonists for the treatment of human SB CD...
  64. ncbi request reprint Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis?
    Stefanie J Schluender
    Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8737 Beverly Boulevard, Suite 101, Los Angeles, California 90048, USA
    Dis Colon Rectum 50:1747-53. 2007
    ..This study was designed to compare short-term complications in patients with ulcerative colitis who were treated with and without infliximab before colectomy...
  65. ncbi request reprint A pilot study of adalimumab in infliximab-allergic patients
    Adrienne Youdim
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 10:333-8. 2004
    ..Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab...
  66. ncbi request reprint TL1A synergizes with IL-12 and IL-18 to enhance IFN-gamma production in human T cells and NK cells
    Konstantinos A Papadakis
    Cedars Sinai Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    J Immunol 172:7002-7. 2004
    ..Our data suggest that TL1A/DR3 pathway plays an important role in the augmentation of cytokine-induced IFN-gamma production in T cells and that DR3 expression is differentially regulated by IL-12/IL-18 in T cells and NK cells...
  67. ncbi request reprint Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease
    Maria T Abreu
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Gastroenterol 40:55-63. 2006
    ..The aim of this study was to assess the ability of treatment with the TNF-alpha antagonist infliximab to increase bone formation as measured by surrogate markers of bone turnover in patients with active CD...
  68. doi request reprint Ustekinumab induction and maintenance therapy in refractory Crohn's disease
    William J Sandborn
    Division of Gastroenterology, University of California San Diego, La Jolla, California 92093 0956, USA
    N Engl J Med 367:1519-28. 2012
    ..In patients with Crohn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and interleukin-23, is unknown...
  69. pmc Recent advances in IBD pathogenesis: genetics and immunobiology
    David Q Shih
    Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Boulevard, Suite D4059, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 10:568-75. 2008
    ..It focuses on advances in our understanding of IBD from the past year, including advances in genetics and immunobiology...
  70. ncbi request reprint Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn
    Eric A Vasiliauskas
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Gastroenterol Hepatol 4:1255-8. 2006
    ..As a result of heightened maternal concern triggered by recent labeling changes, infliximab levels were measured in the newborn of a mother treated with infliximab...
  71. ncbi request reprint CD2 mediates activation of the IFN-gamma intronic STAT binding region in mucosal T cells
    Rivkah Gonsky
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Eur J Immunol 33:1152-62. 2003
    ..Thus, these results indicate that both common as well as unique molecular mechanisms are involved in CD2 signaling and activation of the STAT pathway in LP T cells which are critical for regulation of IFN-gamma expression in the gut...
  72. ncbi request reprint Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab
    Konstantinos A Papadakis
    Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, 8631 W Third Street, Suite 430E, Los Angeles, CA 90048, USA
    Am J Gastroenterol 100:75-9. 2005
    ..The aim of our study was to examine the safety and efficacy of adalimumab (D2E7), a fully humanized anti-TNF-alpha Ab, in CD patients who had experienced an attenuated response to infliximab...
  73. doi request reprint A prospective evaluation of the long-term outcome of ileal pouch-anal anastomosis in patients with inflammatory bowel disease-unclassified and indeterminate colitis
    Zuri A Murrell
    Department of Surgery, Division of Colon and Rectal Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Dis Colon Rectum 52:872-8. 2009
    ..The aim of this study was to prospectively evaluate the long-term outcome of ileal pouch-anal anastomosis in a closely monitored cohort of patients with ulcerative colitis or indeterminate colitis...
  74. pmc Immunopathogenesis of inflammatory bowel disease
    David Q Shih
    Cedars Sinai Inflammatory Bowel Disease Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA
    World J Gastroenterol 14:390-400. 2008
    ....
  75. ncbi request reprint Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses
    Gil Y Melmed
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Medical Center Los Angeles, California 90048, USA
    Am J Gastroenterol 101:1834-40. 2006
    ..We aimed to assess exposure risk and immunization status among patients receiving care in an IBD specialty clinic...
  76. ncbi request reprint State of the art: IBD therapy and clinical trials in IBD
    Kim L Isaacs
    University of North Carolina, Chapel Hill, North Carolina, USA
    Inflamm Bowel Dis 11:S3-12. 2005
    ..The number of products under development and continued investigations into the pathogenesis of IBD emphasize the need to expand clinical research efforts in IBD...
  77. pmc TNFSF15 is an ethnic-specific IBD gene
    Yoana Picornell
    Medical Genetics Institute, Cedars Sinai Medical Center Los Angeles, California, USA
    Inflamm Bowel Dis 13:1333-8. 2007
    ..The aim was to confirm the association between TNFSF15 high- and low-risk haplotypes and IBD in a Caucasian population...
  78. ncbi request reprint Detection of antisynthetic mannoside antibodies (ASigmaMA) reveals heterogeneity in the ASCA response of Crohn's disease patients and contributes to differential diagnosis, stratification, and prediction
    Peggy Vandewalle-El Khoury
    INSERM, U799, Lille, France
    Am J Gastroenterol 103:949-57. 2008
    ....
  79. ncbi request reprint Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype
    Ian D R Arnott
    Gastrointestinal Unit, University of Edinburgh Department of Medical Sciences, School of Clinical and Molecular Medicine, Western General Hospital, Edinburgh EH4 2XU, UK
    Am J Gastroenterol 99:2376-84. 2004
    ..We aimed to assess the frequency of anti-OmpC, anti-I2, ASCA, and pANCA, in an independent Scottish CD cohort, establish phenotypic associations, and compare with a U.S. cohort...
  80. doi request reprint Ex vivo simulation of IgG Fc and T-cell receptor functions: an application to inflammatory bowel disease
    Masato Mitsuhashi
    Hitachi Chemical Research Center, Inc, Irvine, California, USA
    Inflamm Bowel Dis 14:1061-7. 2008
    ..Human leukocyte IgG Fc receptors (FcgammaR) and T-cell receptors (TCR) are primary molecules involved in inflammatory and immune pathways...
  81. pmc Bacterial flagellin is a dominant antigen in Crohn disease
    Michael J Lodes
    Corixa Corp, Seattle, Washington, USA
    J Clin Invest 113:1296-306. 2004
    ....
  82. ncbi request reprint Molecular approaches to the role of the microbiota in inflammatory bowel disease
    Charles O Elson
    Division of Gastroenterology and Hepatology, The University of Alabama Birmingham, 633 Zeigler Research Building, 703 S 19th Street, Birmingham, AL 35294 0007, USA
    Ann N Y Acad Sci 1072:39-51. 2006
    ..Previously unknown microbial flagellins were the dominant cluster of antigens identified. About half of the sera from patients with Crohn's disease have IgG antibodies to these flagellins...
  83. pmc Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis
    John D Rioux
    Université de Montréal and the Montreal Heart Institute, Research Center, 5000 rue Belanger, Montreal, Quebec H1T 1C8, Canada
    Nat Genet 39:596-604. 2007
    ..Together, these findings suggest that autophagy and host cell responses to intracellular microbes are involved in the pathogenesis of Crohn disease...
  84. ncbi request reprint 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
    Marla C Dubinsky
    Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Gastroenterology 122:904-15. 2002
    ..The objectives of this study were to determine whether dose escalation optimizes both 6-TGN levels and efficacy in patients failing therapy because of subtherapeutic 6-TGN levels and its effect on TPMT...
  85. doi request reprint Certolizumab pegol
    Gil Y Melmed
    Nat Rev Drug Discov 7:641-2. 2008
    ..In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have not responded to conventional therapies...
  86. ncbi request reprint Anti-CD2O chimeric monoclonal antibody (rituximab) treatment of immune-mediated thrombocytopenia associated with Crohn's disease
    Konstantinos A Papadakis
    Gastroenterology 124:583. 2003
  87. ncbi request reprint Challenges in IBD Research: updating the scientific agendas
    Charles O Elson
    Division of Gastroenterology, Inflammatory Bowel Disease Center, University of Alabama at Birmingham, USA
    Inflamm Bowel Dis 9:137-53. 2003
  88. ncbi request reprint 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
    Marla C Dubinsky
    Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
    Gastroenterology 125:298-303. 2003
    ..The aim of this study was to describe the association between 6-TG and NRH in IBD...
  89. ncbi request reprint The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease
    Robin Matuk
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 10:352-6. 2004
    ..Treatment with COX-2 inhibitors is associated with a high incidence of exacerbation of the underlying IBD and GI-related complications...
  90. ncbi request reprint Enhancer role of STAT5 in CD2 activation of IFN-gamma gene expression
    Rivkah Gonsky
    Inflammatory Bowel Disease Research Center, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Immunol 173:6241-7. 2004
    ..This report is the first to describe CD2-mediated activation of STAT5 and supports STAT5 involvement in regulation of IFN-gamma expression...
  91. ncbi request reprint Elevated platelet count before ileal pouch-anal anastomosis for ulcerative colitis is associated with the development of chronic pouchitis
    Aderet Okon
    Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am Surg 71:821-6. 2005
    ..03). The incidence of CP was significantly higher after IPAA in UC patients having thrombocytosis before surgery compared to UC patients having a normal platelet count before surgery...
  92. ncbi request reprint The T cell costimulator TL1A is induced by FcgammaR signaling in human monocytes and dendritic cells
    John L Prehn
    Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    J Immunol 178:4033-8. 2007
    ..Furthermore, we demonstrate that TL1A production in monocytes leads to enhancement of T cell responses. The induction of TL1A on APCs via specific pathway stimulation suggests a role for TL1A in Th1 responses to pathogens, and in CD...
  93. pmc Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
    Jeffrey C Barrett
    Bioinformatics and Statistical Genetics, Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK
    Nat Genet 40:955-62. 2008
    ..The expanded molecular understanding of the basis of this disease offers promise for informed therapeutic development...
  94. ncbi request reprint Biologic therapy of inflammatory bowel disease
    William J Sandborn
    Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Gastroenterology 122:1592-608. 2002
    ..Based on the early successes of infliximab, CDP571 and natalizumab, it seems certain that biologic therapy will play an important role in the future treatment of inflammatory bowel disease...

Research Grants25

  1. Role of TL1A in Severity of Crohn's Disease Inflammation
    Stephan R Targan; Fiscal Year: 2010
    ....
  2. IBD--MUCOSA-SPECIFIC REGULATION OF IFN-GAMMA PRODUCTION
    Stephan Targan; Fiscal Year: 2005
    ..abstract_text> ..
  3. IBD:TNF-alpha and Crohn's Disease Mucosal Inflammation
    Stephan Targan; Fiscal Year: 2007
    ..abstract_text> ..
  4. TNF ALPHA AND CROHNS DISEASE MUCOSAL INFLAMMATION
    Stephan Targan; Fiscal Year: 2003
    ..Furthermore, it will allow studies to define new targets for therapeutic approaches aimed at selectively downregulating the TNF-alpha mediated, enhancement of Th1 responses in Crohn's mucosa. ..
  5. ROLE OF ACTIVATED T CELLS IN GUT INJURY
    Stephan Targan; Fiscal Year: 1993
    ..2. Define the regulation of TNF-alpha and IFN-gamma transcription, production and release from mucosal T-cells. 3. Determine the mechanism of TNF-alpha and IFN-gamma synergism of epithelial cell cytoxicity...
  6. IBD--ROLE OF ACTIVATED T-CELLS IN GUT INJURY
    Stephan Targan; Fiscal Year: 2000
    ..3). The constitutive composition of the jun and jun/fos AP-1 in LP-like and LPT cells and whether activation by CD2 and/or CD28 results in differences in the expression in composition of these dimeric proteins. ..